Breast cancers can be classified into subgroups that hint at the aggressiveness of the cancer and the likelihood that the ...

Analysis of the open label data from FLAMINGO-01 has commenced and has been conducted in a manner that maintains the study blind. A preliminary review of FLAMINGO-01 HLA data in both the HLA-A*02 ...

Greenwich LifeSciences, Inc. (Nasdaq: GLSI) (the "Company"), a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, FLAMINGO-01 ...

The news: Clarity Pharmaceuticals shares tumbled after it announced a new treatment in its pipeline for breast cancer. The numbers: The clinical-stage radiopharmaceutical company’s shares dropped 5.36 ...

Six new drugs, including a treatment for patients with advanced breast cancer, have been approved for use by the NHS in Scotland. The Scottish Medicines Consortium (SMC) has given the green light to ...

STAFFORD, Texas - Greenwich LifeSciences, Inc. (NASDAQ:GLSI), a clinical-stage biopharmaceutical company valued at $163 million, has announced the commencement of analysis on the open label HLA data ...

The following highlights showcase the most pivotal, innovative research published across multiple therapeutic areas in ...

National Institute for Sickness and Invalidity Insurance (INAMI-RIZIV) located in Brussels has expanded the reimbursement ...

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...

Chemotherapy for breast cancer may be more effective during specific stages of the menstrual cycle, according to data from ...